Egfr - epidermal growth factor receptor Gene

中文名称：表皮生长因子受体

种属: Rattus norvegicus

同用名: Errp; ERBB1; ErbB-1

基因 ID: 24329 | 基因类型: protein coding

关于 Egfr

Primary_assembly 14: 91,177,067-91,344,382 forward strand.mRatBN7.2:CM026987.1

This gene has 3 transcripts (splice variants), 283 orthologues, 54 paralogues and is associated with 122 phenotypes. Biased expression in Liver (RPKM 29.9), Kidney (RPKM 64.3) and 8 other tissues.

功能概要

该基因编码的蛋白可启动多种功能，包括钙调蛋白结合活性；表皮生长因子结合活性；和表皮生长因子激活受体活性。参与多个过程，包括动物器官发育；神经发生；和细胞通讯的积极调节。位于几种细胞成分中，包括顶端质膜；基底外侧质膜；和细胞质囊泡。用于研究细支气管肺泡腺癌；扩张型心肌病;和高级神经胶质瘤。多种疾病的生物标志物，包括帕金森病；急性肾功能衰竭；肺部疾病（多发）；正中神经病变;和消化性食管炎。该基因的人类直系同源物与多种疾病有关，包括结直肠癌；肺非小细胞癌（多发性）；胰腺癌;前列腺癌;和肺结核。与人类 EGFR（表皮生长因子受体）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables several functions, including Calmodulin binding activity; epidermal growth factor binding activity; and epidermal growth factor-activated receptor activity. Involved in several processes, including animal organ development; neurogenesis; and positive regulation of cell communication. Located in several cellular components, including apical plasma membrane; basolateral plasma membrane; and cytoplasmic vesicle. Used to study bronchiolo-alveolar adenocarcinoma; dilated cardiomyopathy; and high grade glioma. Biomarker of several diseases, including Parkinsonism; acute kidney failure; lung disease (multiple); median neuropathy; and peptic esophagitis. Human ortholog(s) of this gene implicated in several diseases, including colorectal cancer; lung non-small cell carcinoma (multiple); pancreatic cancer; prostate cancer; and pulmonary tuberculosis. Orthologous to human EGFR (epidermal growth factor receptor). [provided by Alliance of Genome Resources, Apr 2022]

Egfr 基因产物(2)

mRNA	Protein	Name
NM_001393707.1	NP_001380636.1	epidermal growth factor receptor isoform 2 precursor
NM_031507.2	NP_113695.2	epidermal growth factor receptor isoform 1 precursor

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables calmodulin binding	IDA IDA: 通过直接分析推断	9788758	RGD
enables epidermal growth factor binding	IMP IMP: 通过突变表型推断	15486316	RGD
enables epidermal growth factor receptor activity	IDA IDA: 通过直接分析推断	11796513	RGD
enables epidermal growth factor receptor activity	IMP IMP: 通过突变表型推断	15486316	RGD
enables integrin binding	IPI IPI: 通过物理相互作用推断	21349584	RGD
enables protein binding	IPI IPI: 通过物理相互作用推断	21037565	RGD
enables protein kinase binding	IPI IPI: 通过物理相互作用推断	21037565	RGD
enables protein phosphatase binding	IPI IPI: 通过物理相互作用推断	11157073	RGD
enables protein tyrosine kinase activity	IDA IDA: 通过直接分析推断	9788758	RGD
enables protein-containing complex binding	IPI IPI: 通过物理相互作用推断	16769812	RGD
enables signaling receptor binding	IPI IPI: 通过物理相互作用推断	21349584	RGD

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in astrocyte activation	IMP IMP: 通过突变表型推断	16837601	RGD
involved in cellular response to dexamethasone stimulus	IEP IEP: 通过表达模式推断	17585012	RGD
involved in cellular response to epidermal growth factor stimulus	IDA IDA: 通过直接分析推断	20639532	RGD
involved in cellular response to growth factor stimulus	IEP IEP: 通过表达模式推断	3495539	RGD
involved in cellular response to mechanical stimulus	IEP IEP: 通过表达模式推断	20927110	RGD
involved in cellular response to xenobiotic stimulus	IEP IEP: 通过表达模式推断	21276422	RGD
involved in circadian rhythm	IEP IEP: 通过表达模式推断	12454858	RGD
involved in diterpenoid metabolic process	IEP IEP: 通过表达模式推断	21448670	RGD
involved in epidermal growth factor receptor signaling pathway	IDA IDA: 通过直接分析推断	11796513	RGD
involved in epidermal growth factor receptor signaling pathway	IMP IMP: 通过突变表型推断	15486316	RGD
involved in hair follicle development	IEP IEP: 通过表达模式推断	6088642	RGD
involved in hydrogen peroxide metabolic process	IEP IEP: 通过表达模式推断	21258655	RGD
involved in intracellular signal transduction	IDA IDA: 通过直接分析推断	12107054	RGD
involved in learning or memory	IDA IDA: 通过直接分析推断	20639532	RGD
involved in liver development	IEP IEP: 通过表达模式推断	12454858	RGD
involved in liver regeneration	IEP IEP: 通过表达模式推断	2401457	RGD
involved in liver regeneration	IMP IMP: 通过突变表型推断	20395437	RGD
involved in lung development	IEP IEP: 通过表达模式推断	20118217	RGD
involved in midgut development	IEP IEP: 通过表达模式推断	7926492	RGD
involved in negative regulation of apoptotic process	IMP IMP: 通过突变表型推断	16466740	RGD
involved in negative regulation of mitotic cell cycle	IMP IMP: 通过突变表型推断	14551192	RGD
involved in neuron projection morphogenesis	IMP IMP: 通过突变表型推断	16648628	RGD
involved in ovulation cycle	IMP IMP: 通过突变表型推断	11796513	RGD
involved in peptidyl-tyrosine phosphorylation	IDA IDA: 通过直接分析推断	9788758	RGD
involved in positive regulation of MAPK cascade	IMP IMP: 通过突变表型推断	14551192	RGD
involved in positive regulation of bone resorption	IMP IMP: 通过突变表型推断	2981075	RGD
involved in positive regulation of glial cell proliferation	IMP IMP: 通过突变表型推断	10616092	RGD
involved in positive regulation of mucus secretion	IMP IMP: 通过突变表型推断	29183867	RGD
involved in positive regulation of prolactin secretion	IDA IDA: 通过直接分析推断	6195656	RGD
involved in positive regulation of smooth muscle cell proliferation	IMP IMP: 通过突变表型推断	15486316	RGD
involved in positive regulation of superoxide anion generation	IMP IMP: 通过突变表型推断	22966991	RGD
involved in positive regulation of synaptic transmission, glutamatergic	IMP IMP: 通过突变表型推断	16648628	RGD
involved in positive regulation of vasoconstriction	IMP IMP: 通过突变表型推断	22966991	RGD
involved in protein autophosphorylation	IDA IDA: 通过直接分析推断	3015391	RGD
involved in response to calcium ion	IMP IMP: 通过突变表型推断	15950968	RGD
involved in response to cobalamin	IEP IEP: 通过表达模式推断	21185268	RGD
involved in response to estradiol	IEP IEP: 通过表达模式推断	2991264	RGD
involved in response to hydroxyisoflavone	IEP IEP: 通过表达模式推断	21254785	RGD
involved in response to lipid	IEP IEP: 通过表达模式推断	15044318	RGD
involved in response to organic cyclic compound	IEP IEP: 通过表达模式推断	21475988	RGD
involved in response to oxidative stress	IEP IEP: 通过表达模式推断	11208719	RGD
involved in tongue development	IEP IEP: 通过表达模式推断	10908606	RGD
involved in translation	IDA IDA: 通过直接分析推断	12107054	RGD
involved in vasodilation	IMP IMP: 通过突变表型推断	23232926	RGD

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in apical plasma membrane	IDA IDA: 通过直接分析推断	15631999	RGD
located in basolateral plasma membrane	IDA IDA: 通过直接分析推断	15631999	RGD
located in cell surface	IDA IDA: 通过直接分析推断	21349584	RGD
located in endocytic vesicle	IDA IDA: 通过直接分析推断	11071913	RGD
located in endosome	IDA IDA: 通过直接分析推断	21172338	RGD
is active in glutamatergic synapse	EXP EXP: 通过实验结果推断	27565350	RGD
is active in glutamatergic synapse	IDA IDA: 通过直接分析推断	27565350	RGD
is active in synaptic membrane	EXP EXP: 通过实验结果推断	27565350	RGD
is active in synaptic membrane	IDA IDA: 通过直接分析推断	27565350	RGD

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Egfr 蛋白结构

Recep_L_domain

Furin-like

Recep_L_domain

GF_recep_IV

TM_ErbB1

PTKc_EGFR

0
200
400
600
800
1000
1209 a.a.

蛋白主名

其他名称

epidermal growth factor receptor

EGFR-related peptide	Epidermal growth factor receptor formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1)
avian erythroblastic leukemia viral (v-erbB) oncogene homolog	epidermal growth factor receptor, formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1)

重组 Egfr 蛋白

目录号	产品名	蛋白编号	纯度
HY-P72990	EGFR Protein, Rat (HEK293, His)	E7CXR8 (L25-S646)	≥95%

相关产品

Approval

生物活性分子 (43)

目录号	产品名	作用方式	纯度	是否罕见病
HY-15772	Osimertinib	Inhibitor	99.96%	是
HY-50895	Gefitinib	Inhibitor	99.94%	是
HY-50896	Erlotinib	Inhibitor	99.99%	是
HY-10261	Afatinib	Inhibitor	99.92%	是
HY-138298A	Trastuzumab deruxtecan	Inhibitor	99.68%	否
HY-50898	Lapatinib	Inhibitor	99.83%	是
HY-138298	Trastuzumab deruxtecan (solution)	Inhibitor	99.64%	否
HY-P9921	Trastuzumab emtansine	Inhibitor	99.74%	否
HY-16069	Tucatinib	Inhibitor	99.82%	是
HY-32721	Neratinib	Inhibitor	99.94%	是
HY-P9985	Disitamab vedotin	Inhibitor	≥99.0%	否
HY-13272	Dacomitinib	Inhibitor	99.74%	是
HY-15772A	Osimertinib mesylate	Inhibitor	99.97%	是
HY-12008	Erlotinib Hydrochloride	Inhibitor	99.93%	是
HY-109061	Lazertinib	Inhibitor	99.07%	否
HY-135815	Mobocertinib	Inhibitor	99.60%	是
HY-112823	Almonertinib	Inhibitor	99.98%	否
HY-104065	Pyrotinib	Inhibitor	99.89%	否
HY-112870A	Firmonertinib mesylate	Inhibitor	99.97%	否
HY-15164A	Icotinib	Inhibitor	99.99%	是
HY-10261A	Afatinib dimaleate	Inhibitor	99.88%	是
HY-N0281	Daphnetin	Inhibitor	99.86%	否
HY-50895A	Gefitinib hydrochloride	Inhibitor	99.85%	是
HY-19730	Olmutinib	Inhibitor	99.88%	否
HY-79077	Osimertinib dimesylate	Inhibitor	99.96%	是
HY-P9921A	Trastuzumab emtansine (solution)		99.01%	否
HY-50898A	Lapatinib ditosylate	Inhibitor	99.98%	是
HY-104065B	Pyrotinib dimaleate	Inhibitor	98.56%	否
HY-15164	Icotinib Hydrochloride	Inhibitor	99.81%	是
HY-50898B	Lapatinib ditosylate monohydrate	Inhibitor	99.93%	是
HY-112823A	Almonertinib mesylate	Inhibitor	99.07%	否
HY-112823B	Almonertinib hydrochloride	Inhibitor	99.77%	否
HY-32721B	Neratinib maleate	Inhibitor	99.83%	是
HY-135815A	Mobocertinib succinate	Inhibitor	99.83%	是
HY-118263	Dacomitinib hydrate	Inhibitor	99.03%	否
HY-112870	Firmonertinib	Inhibitor	99.89%	否
HY-50895R	Gefitinib (Standard)	Inhibitor	/	否
HY-10261D	Afatinib oxalate	Inhibitor	/	否
HY-135815B	Mobocertinib mesylate	Inhibitor	/	否
HY-50895B	Gefitinib dihydrochloride	Inhibitor	/	否
HY-50898C	Lapatinib tosylate	Inhibitor	/	否
HY-101820A	Simotinib hydrochloride	Inhibitor	/	否
HY-12008A	Erlotinib mesylate	Inhibitor	/	否

抗体抑制剂 (9)

目录号	产品名	作用方式	纯度	是否罕见病
HY-P9907	Trastuzumab	Inhibitor	99.80%	否
HY-P9905	Cetuximab	Inhibitor	99.70%	否
HY-P9977	Amivantamab	Inhibitor	99.90%	否
HY-P9912	Pertuzumab	Inhibitor	99.80%	否
HY-P99041	Panitumumab	Inhibitor	98.80%	否
HY-P99380	Zanidatamab	Inhibitor	96.38%	否
HY-P9968	Nimotuzumab	Inhibitor	96.80%	否
HY-P99030	Margetuximab	Inhibitor	98.90%	否
HY-P9964	Necitumumab	Inhibitor	95.00%	否

Clinical Phase

生物活性分子 (60)

目录号	产品名	作用方式	纯度	Phase
HY-14596	Genistein	Inhibitor	99.86%	Phase 4
HY-50895G	Gefitinib (GMP)	Inhibitor	/	Phase 4
HY-132842	Sunvozertinib	Inhibitor	99.92%	Phase 3
HY-18750	Zorifertinib	Inhibitor	99.76%	Phase 3
HY-15729	Rociletinib	Inhibitor	99.79%	Phase 3
HY-13314	Tesevatinib	Inhibitor	99.21%	Phase 3
HY-19816	Avitinib	Inhibitor	99.90%	Phase 3
HY-10530	Varlitinib	Inhibitor	98.03%	Phase 3
HY-19816A	Avitinib maleate	Inhibitor	≥98.0%	Phase 3
HY-19803	Naquotinib mesylate	Inhibitor	98.05%	Phase 3
HY-16069A	Tucatinib hemiethanolate	Inhibitor	99.97%	Phase 3
HY-138751	limertinib	Inhibitor	99.12%	Phase 3
HY-19729	Naquotinib	Inhibitor	98.71%	Phase 3
HY-132259	Depatuxizumab mafodotin		99.73%	Phase 3
HY-15729A	Rociletinib hydrobromide	Inhibitor	98.04%	Phase 3
HY-118998	TX2-121-1	Inhibitor	/	Phase 3
HY-10530A	Varlitinib tosylate	Inhibitor	/	Phase 3
HY-106204	Nelipepimut-S		/	Phase 3
HY-13050	Sapitinib	Inhibitor	99.93%	Phase 2
HY-144680	BLU-945	Inhibitor	99.90%	Phase 2
HY-18957	Lifirafenib	Inhibitor	98.73%	Phase 2
HY-10367	Canertinib	Inhibitor	99.82%	Phase 2
HY-32718	Pelitinib	Inhibitor	98.80%	Phase 2
HY-10333	BMS-690514	Inhibitor	99.07%	Phase 2
HY-112299	Zipalertinib	Inhibitor	99.81%	Phase 2
HY-10045	AEE788	Inhibitor	99.13%	Phase 2
HY-12872	Nazartinib	Inhibitor	99.03%	Phase 2
HY-12972	Mavelertinib	Inhibitor	99.34%	Phase 2
HY-136789	Tuxobertinib	Inhibitor	99.90%	Phase 2
HY-19985	PF-06459988	Inhibitor	98.87%	Phase 2
HY-10367A	Canertinib dihydrochloride	Inhibitor	99.68%	Phase 2
HY-107367A	Epertinib hydrochloride	Inhibitor	98.25%	Phase 2
HY-157229	STX-721	Inhibitor	98.25%	Phase 2
HY-17632	Tarloxotinib bromide	Inhibitor	99.26%	Phase 2
HY-19909	NRC-2694	Antagonist	99.45%	Phase 2
HY-107367	Epertinib	Inhibitor	≥98.0%	Phase 2
HY-12872A	Nazartinib mesylate	Inhibitor	/	Phase 2
HY-10223	CUDC-101	Inhibitor	98.84%	Phase 1
HY-13501	Mubritinib	Inhibitor	99.91%	Phase 1
HY-14346	PD153035	Inhibitor	98.83%	Phase 1
HY-15196	TAK-285	Inhibitor	99.70%	Phase 1
HY-10322	Falnidamol	Inhibitor	99.05%	Phase 1
HY-B0794B	AZ7550 Mesylate	Inhibitor	99.24%	Phase 1
HY-101820	Simotinib	Inhibitor	99.39%	Phase 1
HY-103443	HKI-357	Inhibitor	99.65%	Phase 1
HY-116437	Selatinib	Inhibitor	99.83%	Phase 1
HY-12010	BMS-599626 Hydrochloride	Inhibitor	99.68%	Phase 1
HY-10346A	AV-412 free base	Inhibitor	98.33%	Phase 1
HY-104066	Theliatinib	Inhibitor	99.77%	Phase 1
HY-111553	TAS0728	Inhibitor	99.15%	Phase 1
HY-143319	SPH5030	Inhibitor	99.40%	Phase 1
HY-139300A	Epitinib succinate	Inhibitor	99.01%	Phase 1
HY-10346	AV-412	Inhibitor	99.17%	Phase 1
HY-128778	DBPR112	Inhibitor	98.37%	Phase 1
HY-B0794A	AZ7550 hydrochloride	Inhibitor	98.66%	Phase 1
HY-15732	BGB-102	Inhibitor	99.52%	Phase 1
HY-104066A	Theliatinib tartrate		/	Phase 1
HY-139300	Epitinib	Inhibitor	/	Phase 1
HY-10251	BMS-599626	Inhibitor	/	Phase 1
HY-18957B	Lifirafenib maleate	Inhibitor	/	Phase 1

抗体抑制剂 (30)

目录号	产品名	作用方式	纯度	Phase
HY-P9907A	Trastuzumab (anti-HER2)	Inhibitor	99.72%	Phase 4
HY-P99854	Disitamab	Inhibitor	≥95.0%	Phase 4
HY-P99041A	Panitumumab (anti-EGFR)	Inhibitor	98.00%	Phase 4
HY-P99969	Inetetamab	Inhibitor	96.54%	Phase 4
HY-P99275	Patritumab	Inhibitor	98.95%	Phase 3
HY-P99849	Depatuxizumab	Inhibitor	99.58%	Phase 3
HY-P99155	Zalutumumab		98.26%	Phase 3
HY-P99676	Izalontamab	Inhibitor	99.03%	Phase 3
HY-P99455	Bafisontamab	Inhibitor	96.00%	Phase 3
HY-P99437	Anbenitamab	Inhibitor	99.22%	Phase 3
HY-P99831	Coprelotamab		/	Phase 3
HY-P99630	Gancotamab	Inhibitor	/	Phase 3
HY-P99268	Seribantumab	Inhibitor	≥95.0%	Phase 2
HY-P99507	Zenocutuzumab	Inhibitor	99.20%	Phase 2
HY-P99406	Petosemtamab	Degrader	96.95%	Phase 2
HY-P9969	Matuzumab		98.12%	Phase 2
HY-P99936	Elgemtumab	Inhibitor	99.00%	Phase 2
HY-P990049	Becotatug	Inhibitor	98.44%	Phase 2
HY-P99618	Fidasimtamab	Inhibitor	95.00%	Phase 2
HY-P99216	Ponezumab	Inhibitor	99.39%	Phase 2
HY-P99306	Modotuximab	Inhibitor	99.08%	Phase 2
HY-P99866	Duligotuzumab		97.93%	Phase 2
HY-P99715	Losatuxizumab	Inhibitor	99.44%	Phase 2
HY-P99296	Intetumumab	Inhibitor	99.24%	Phase 2
HY-P99605	Cinrebafusp alfa	Inhibitor	98.53%	Phase 2
HY-P99295	Imgatuzumab	Inhibitor	99.41%	Phase 2
HY-P99628	Futuximab	Inhibitor	/	Phase 2
HY-P99672	Istiratumab	Inhibitor	/	Phase 2
HY-P99304	Lumretuzumab	Inhibitor	≥99.0%	Phase 1
HY-P99461	Barecetamab	Inhibitor	97.96%	Phase 1

Pre-clinical Phase

生物活性分子 (536)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-12000	AG490	Inhibitor	99.92%	否
HY-13524	AG-1478	Inhibitor	99.22%	否
HY-101084	NSC 228155	Activator	≥98.0%	否
HY-N2409	Delphinidin chloride	Inhibitor	≥98.0%	否
HY-13595	Chrysophanol	Inhibitor	99.77%	否
HY-N0280	Corosolic acid		99.23%	否
HY-100848	TX1-85-1	Inhibitor	98.04%	否
HY-16558	Butein	Inhibitor	99.95%	否
HY-12461	WS6	Activator	99.94%	否
HY-100213	EAI045	Inhibitor	99.08%	否
HY-123921	Gefitinib-based PROTAC 3	Inhibitor	99.98%	否
HY-P10408	Candidalysin	Activator	99.38%	否
HY-15730	Poziotinib	Inhibitor	99.96%	否
HY-B0793	AZ-5104	Inhibitor	99.70%	否
HY-14674	CP-724714	Inhibitor	98.53%	否
HY-15644	Tyrphostin 23	Inhibitor	99.43%	否
HY-129550	BI-4020	Inhibitor	99.28%	否
HY-13896	PD168393	Inhibitor	98.58%	否
HY-18609	PD158780	Inhibitor	99.56%	否
HY-12026	WZ4002	Inhibitor	99.76%	否
HY-15844	AG-825	Inhibitor	98.02%	否
HY-147183B	JBJ-09-063 hydrochloride	Inhibitor	99.37%	否
HY-108052	Delphinidin 3-glucoside chloride	Inhibitor	99.89%	否
HY-109189	Rezivertinib	Inhibitor	99.43%	否
HY-141676	HyT36	Degrader	≥96.0%	否
HY-13427	Allitinib tosylate	Inhibitor	99.83%	否
HY-N2450	Sulforaphene	Inhibitor	99.80%	否
HY-W016412	Coenzyme Q0	Inhibitor	99.88%	否
HY-153268	BDTX-1535	Inhibitor	99.03%	否
HY-20878	Tyrphostin AG 879	Inhibitor	99.85%	否
HY-14596R	Genistein (Standard)	Inhibitor	99.31%	否
HY-14596S	Genistein-d4	Inhibitor	98.81%	否
HY-12001	WZ-3146	Inhibitor	99.63%	否
HY-111138	CZC-8004	Inhibitor	99.81%	否
HY-123578	NSC689857	Inhibitor	99.65%	否
HY-N0211	Cyasterone	Inhibitor	99.58%	否
HY-P1845	PACAP-38 (31-38), human, mouse, rat	Inducer	99.98%	否
HY-P1845A	PACAP-38 (31-38), human, mouse, rat TFA	Inducer	98.33%	否
HY-112411	PD 174265	Inhibitor	98.72%	否
HY-13895	WHI-P154	Inhibitor	99.39%	否
HY-162713	MTX-531	Inhibitor	99.87%	否
HY-147941A	MS9427 TFA	Degrader	99.01%	否
HY-78869	Mutated EGFR-IN-1	Inhibitor	99.84%	否
HY-144880	SC209	Inhibitor	99.52%	否
HY-107364	MTX-211	Inhibitor	99.81%	否
HY-137191	CH7233163	Inhibitor	99.61%	否
HY-N2510	Myristicin	Inhibitor	99.89%	否
HY-101219	VEGFR-IN-1	Inhibitor	98.42%	否
HY-10325	CL-387785	Inhibitor	98.05%	否
HY-150024	BI-4142	Inhibitor	98.39%	否
HY-137433	Befotertinib	Inhibitor	99.86%	否
HY-142283AS	Dosimertinib mesylate	Inhibitor	99.44%	否
HY-10261B	(E/Z)-Afatinib	Inhibitor	99.98%	否
HY-155537	YK-029A	Inhibitor	99.50%	否
HY-12029	WZ8040	Inhibitor	99.22%	否
HY-19815	Olafertinib	Inhibitor	99.51%	否
HY-134877	BAY 2476568	Inhibitor	99.88%	否
HY-135805A	(Rac)-JBJ-04-125-02	Inhibitor	/	否
HY-141640	MS154	Inhibitor	99.42%	否
HY-147219A	SIAIS164018 hydrochloride	Inhibitor	99.84%	否
HY-124813	PDZ1i	Inhibitor	99.29%	否
HY-N1166	Tephrosin		98.02%	否
HY-150611	EGFR-IN-70	Inhibitor	99.16%	否
HY-43533	Tarlox-TKI	Inhibitor	98.84%	否
HY-15801	HG-14-10-04	Inhibitor	99.09%	否
HY-103440	EGFR/ErbB-2/ErbB-4 inhibitor-3	Inhibitor	98.19%	否
HY-12013	PD153035 Hydrochloride	Inhibitor	99.48%	否
HY-150023	BI-1622	Inhibitor	98.97%	否
HY-147183A	JBJ-09-063 TFA	Inhibitor	99.64%	否
HY-153110A	Larotinib mesylate hydrate	Inhibitor	98.66%	否
HY-139920	Oritinib	Inhibitor	99.18%	否
HY-138627A	AST5902 trimesylate	Inhibitor	98.75%	否
HY-101450	PF-6274484	Inhibitor	98.76%	否
HY-115481	EphB1-IN-1	Inhibitor	99.87%	否
HY-120590	Ruserontinib	Inhibitor	99.82%	否
HY-107459	(E/Z)-AG490	Inhibitor	99.97%	否
HY-103566	LY456236	Inhibitor	99.81%	否
HY-101042	AG-494	Inhibitor	99.31%	否
HY-100434	PD-161570	Inhibitor	99.82%	否
HY-B1394	Khellin	Inhibitor	99.89%	否
HY-124674A	CCT365623 hydrochloride	Inhibitor	98.07%	否
HY-112420	EGFR/ErbB-2/ErbB-4 inhibitor-2	Inhibitor	99.45%	否
HY-18603	FIIN-3	Inhibitor	99.66%	否
HY-147942	MS9449		98.95%	否
HY-136430	JCN037	Inhibitor	99.76%	否
HY-141481	DP-C-4	Inhibitor	98.15%	否
HY-41404	Piperonylic acid		99.91%	否
HY-101960A	Tyrphostin A51	Inhibitor	≥99.0%	否
HY-101429	RG13022	Inhibitor	96.74%	否
HY-17499	EGFR-IN-12	Inhibitor	99.40%	否
HY-112293	GW2974		99.54%	否
HY-P5314	OK2	Inhibitor	95.95%	否
HY-144304	PROTAC EGFR degrader 2	Inhibitor	95.61%	否
HY-N4201	β-Hydroxyisovalerylshikonin	Inhibitor	99.83%	否
HY-117155	PKI-166	Inhibitor	99.58%	否
HY-123952	RTC-5	Inhibitor	99.89%	否
HY-12008S	Erlotinib-d6 hydrochloride	Inhibitor	98.13%	否
HY-113599	Isoprocurcumenol	Activator	95.41%	否
HY-15769	WHI-P180	Inhibitor	99.62%	否
HY-131865	SJF-1521	Degrader	99.65%	否
HY-101041	(E)-AG 556	Inhibitor	99.92%	否
HY-100214	EAI001	Inhibitor	99.88%	否
HY-130616	EGFR-IN-11	Inhibitor	99.30%	否
HY-155079	DZD1516		98.31%	否
HY-133780	Afatinib impurity 11	Inhibitor	99.10%	否
HY-100499	Tyrphostin AG 528	Inhibitor	≥98.0%	否
HY-155736	MAPK-IN-2	Inhibitor	98.54%	否
HY-157581	MS39	Degrader	99.2%	否
HY-18963	Lavendustin A	Inhibitor	98.02%	否
HY-135805B	(Rac)-JBJ-04-125-02 acetate		96.58%	否
HY-112345	PD-089828	Inhibitor	98.07%	否
HY-N2184	Furanodienone		99.90%	否
HY-153901	PROTAC EGFR degrader 8	Inhibitor	98.90%	否
HY-W018800	4(3H)-Quinazolinone	Inhibitor	99.91%	否
HY-101426	RG14620	Inhibitor	98.09%	否
HY-13984	Mutant EGFR inhibitor	Inhibitor	99.51%	否
HY-108016	Peruvoside	Inhibitor	99.32%	否
HY-103442	CGP52411	Inhibitor	99.82%	否
HY-108484	PP 3	Inhibitor	98.78%	否
HY-157480	EGFR/AURKB-IN-1	Inhibitor	99.43%	否
HY-10261S	Afatinib-d6	Inhibitor	≥99.0%	否
HY-13897	CNX-2006	Inhibitor	98.42%	否
HY-131864A	SJF-1528 hemihydrate	Degrader	98.90%	否
HY-128862	EGFR-IN-7	Inhibitor	99.76%	否
HY-126320	EGFR-IN-8	Inhibitor	98.01%	否
HY-100962	(E)-AG 99	Inhibitor	98.36%	否
HY-111415	EGFR-IN-5	Inhibitor	98.64%	否
HY-W013857	Lavendustin C	Inhibitor	98.32%	否
HY-156284	EGFR-IN-89	Inhibitor	98.75%	否
HY-161536	PROTAC EGFR degrader 9	Inhibitor	98.35%	否
HY-138072	EMI1	Inhibitor	99.78%	否
HY-15336	AG 555	Inhibitor	≥98.0%	否
HY-118532	Tyrphostin AG30	Inhibitor	99.70%	否
HY-P1855	HER2/neu (654-662) GP2		98.04%	否
HY-161927	EGFR-TK-IN-4	Inhibitor	99.90%	否
HY-163094	EGFR-IN-95	Inhibitor	/	否
HY-100923	H-9 Dihydrochloride	Inhibitor	98.98%	否
HY-142512	EGFR-IN-24	Inhibitor	/	否
HY-10531	ARRY-380 analog	Inhibitor	99.19%	否
HY-15772S1	Osimertinib-13C,d3		99.14%	否
HY-161537	EGFR ligand-9	Inhibitor	98.80%	否
HY-149889	EGFR-IN-78	Inhibitor	/	否
HY-N6577	Astragaloside VI		99.95%	否
HY-147858	PROTAC EGFR degrader 7	Inhibitor	99.99%	否
HY-161126	EGFR-IN-98	Inhibitor	/	否
HY-149530	EGFR-IN-86	Inhibitor	/	否
HY-162299	EGFR kinase inhibitor 3	Inhibitor	/	否
HY-153111	EGFR/HER2-IN-9	Inhibitor	98.73%	否
HY-50898S	Lapatinib-d4	Inhibitor	99.02%	否
HY-103441	JNJ28871063 hydrochloride	Inhibitor	98.36%	否
HY-W087187	DOTAGA-anhydride		/	否
HY-U00002	ZD-4190	Inhibitor	98.08%	否
HY-15772S	Osimertinib-d6	Inhibitor	99.97%	否
HY-50895S	Gefitinib-d8	Inhibitor	98.42%	否
HY-19617A	EGFR-IN-1 hydrochloride	Inhibitor	/	否
HY-119944	JND3229	Inhibitor	99.78%	否
HY-145960	MC-Val-Cit-PAB-Amide-TLR7 agonist 4	Agonist	99.39%	否
HY-130608	Mutated EGFR-IN-3	Inhibitor	/	否
HY-147183	JBJ-09-063	Inhibitor	/	否
HY-147941	MS9427	Degrader	95.29%	否
HY-153110	Larotinib	Inhibitor	99.50%	否
HY-147219	SIAIS164018	Inhibitor	/	否
HY-132842A	(S)-Sunvozertinib	Inhibitor	99.14%	否
HY-138627	AST5902	Inhibitor	/	否
HY-19617	EGFR-IN-1	Inhibitor	/	否
HY-115716	EGFR-IN-17	Inhibitor	98.42%	否
HY-135805	JBJ-04-125-02	Inhibitor	/	否
HY-155285	YS-363	Inhibitor	99.52%	否
HY-50895S1	Gefitinib-d6	Inhibitor	≥98.0%	否
HY-155358	Os30	Inhibitor	98.34%	否
HY-158310	SOS1/EGFR-IN-1	Inhibitor	99.54%	否
HY-143337	EGFR-IN-47	Inhibitor	96.01%	否
HY-B0794	AZ7550	Inhibitor	/	否
HY-13272S2	Dacomitinib-d10 dihydrochloride	Inhibitor	≥95.0%	否
HY-152098	HX103	Inhibitor	99.10%	否
HY-150610	EGFR-IN-69	Inhibitor	99.58%	否
HY-162254	EGFR/ACK1-IN-1	Inhibitor	/	否
HY-12872B	Nazartinib S-enantiomer		98.66%	否
HY-149636	Multi-target kinase inhibitor 2	Inhibitor	99.82%	否
HY-146349	PROTAC EGFR degrader 4	Inhibitor	/	否
HY-161408	GePhos1		/	否
HY-126319	SU5204	Inhibitor	99.46%	否
HY-103439	GW583340 dihydrochloride	Inhibitor	/	否
HY-157579	MS154N		99.30%	否
HY-144677	pan-HER-IN-2	Inhibitor	98.10%	否
HY-161633	PROTAC EGFR degrader 11	Degrader	/	否
HY-131864	SJF-1528	Degrader	99.71%	否
HY-161275	BI-4732	Inhibitor	97.74%	否
HY-12806	AG1557	Inhibitor	99.54%	否
HY-P2503	EGFR Protein Tyrosine Kinase Substrate		99.05%	否
HY-19617B	EGFR-IN-1 TFA	Inhibitor	99.38%	否
HY-50896S	Erlotinib-d6	Inhibitor	/	否
HY-101007A	(+)-Tyrphostin B44	Inhibitor	97.01%	否
HY-155005	EGFR mutant-IN-2	Inhibitor	≥97.0%	否
HY-101006	Methyl 2,5-dihydroxycinnamate	Inhibitor	99.70%	否
HY-111452	EGFR-IN-85	Inhibitor	/	否
HY-P2673	Lys-Arg-Thr-Leu-Arg-Arg		/	否
HY-157413	YS-67	Inhibitor	99.41%	否
HY-158149	T-1-PMPA	Inhibitor	99.70%	否
HY-13450	ZM 449829	Inhibitor	99.73%	否
HY-101756	SDZ281-977		98.00%	否
HY-138751A	limertinib diTFA	Inhibitor	≥98.0%	否
HY-15375	Allitinib	Inhibitor	99.36%	否
HY-18750A	Zorifertinib hydrochloride	Inhibitor	/	否
HY-142283	Dosimertinib	Inhibitor	/	否
HY-19981B	Derazantinib dihydrochloride	Inhibitor	/	否
HY-135914	JBJ-02-112-05	Inhibitor	/	否
HY-163428	ZN-A-1041	Inhibitor	/	否
HY-128860	Mutated EGFR-IN-2	Inhibitor	/	否
HY-163354	EGFR-IN-103	Inhibitor	/	否
HY-143734	HER2-IN-6		/	否
HY-132883	EGFR/CSC-IN-1	Inhibitor	/	否
HY-131067	EMI56	Inhibitor	99.72%	否
HY-115951	EGFR/HER2-IN-2	Inhibitor	/	否
HY-10407G	SU 5402 (GMP)	Inhibitor	/	否
HY-125841	EGFR mutant-IN-1	Inhibitor	/	否
HY-139920A	Oritinib mesylate	Inhibitor	/	否
HY-147303	Sacibertinib	Inhibitor	/	否
HY-131066	EMI48	Inhibitor	99.02%	否
HY-138746	EGFR-IN-15	Inhibitor	/	否
HY-144048	EGFR-IN-31		/	否
HY-143729	EGFR-IN-29	Inhibitor	/	否
HY-161781	HVH-2930	Inhibitor	/	否
HY-123891	NS-062	Inhibitor	/	否
HY-163657	HER2-IN-20	Inhibitor	/	否
HY-RS04209	EGFR Human Pre-designed siRNA Set A	Inhibitor	/	否
HY-162483	EGFR kinase inhibitor 6	Inhibitor	/	否
HY-13272S3	Dacomitinib-d10	Inhibitor	/	否
HY-100636A	Gefitinib N-oxide hydrochloride	Inhibitor	/	否
HY-RS04211	Egfr Rat Pre-designed siRNA Set A	Inhibitor	/	否
HY-158018	EGFR-TK-IN-2	Inhibitor	/	否
HY-162482	EGFR kinase inhibitor 5	Inhibitor	/	否
HY-158829	SSOe26 sodium		/	否
HY-112405	BPIQ-I	Inhibitor	/	否
HY-153557A	HER2-IN-14	Inhibitor	/	否
HY-10261AS	Afatinib-d6 dimaleate	Inhibitor	/	否
HY-157402	Topoisomerase II/EGFR-IN-1		/	否
HY-163632	EGFR-IN-112	Inhibitor	/	否
HY-100064S1	O-Desmethyl gefitinib-d6	Inhibitor	/	否
HY-147741	DPPY	Inhibitor	/	否
HY-143246	EGFR kinase inhibitor 1	Inhibitor	/	否
HY-158828	SSO111 sodium		/	否
HY-168170	EGFR/VEGFR2-IN-2	Inhibitor	/	否
HY-158153	EGFR-IN-108	Inhibitor	/	否
HY-157399	EGFR/HER2-IN-10	Inhibitor	/	否
HY-163726	GLUT1/EGFR-IN-1	Inhibitor	/	否
HY-145823	EGFR-IN-42	Inhibitor	/	否
HY-144050	EGFR-IN-33	Inhibitor	/	否
HY-152144	EGFR-IN-75	Inhibitor	/	否
HY-146239	EGFR/HER2/TS-IN-2	Inhibitor	/	否
HY-149556	MTX-241F	Inhibitor	/	否
HY-164489	KU004	Inhibitor	/	否
HY-149824	EGFR T790M/L858R-IN-2	Inhibitor	99.66%	否
HY-164307	Pebezertinib	Inhibitor	99.56%	否
HY-149517	EGFR/BRAFV600E-IN-2	Inhibitor	/	否
HY-143323	HER2-IN-9	Inhibitor	/	否
HY-168655	EGFR/VEGFR2-IN-3	Inhibitor	/	否
HY-103437	EGFR-IN-80	Inhibitor	/	否
HY-163402	EGFR-IN-108 chloride	Inhibitor	/	否
HY-163434	PRMT5/EGFR-IN-1	Inhibitor	/	否
HY-137028	2′-Thioadenosine	Inhibitor	/	否
HY-158154	EGFR-IN-110	Inhibitor	/	否
HY-156912	Tyrosine kinase-IN-7	Inhibitor	99.25%	否
HY-155227	ALK/EGFR-IN-1	Inhibitor	/	否
HY-113549	Erbstatin	Inhibitor	/	否
HY-157994	EGFR WT/T790M-IN-2	Inhibitor	/	否
HY-163723	EGFR-IN-116	Inhibitor	/	否
HY-168073	EGFR/VEGFR2-IN-1	Inhibitor	/	否
HY-150781	EGFR-IN-71	Inhibitor	/	否
HY-168514	SOS1/EGFR-IN-2	Inhibitor	/	否
HY-141486A	PROTAC PARP/EGFR ligand 1		/	否
HY-146474	EGFR-IN-54	Inhibitor	/	否
HY-157432	EGFR-IN-97	Inhibitor	/	否
HY-147796	EGFR/HER2/CDK9-IN-1	Inhibitor	/	否
HY-110333	BMS-599626 dihydrochloride	Inhibitor	/	否
HY-151882	EGFR-IN-73	Inhibitor	/	否
HY-146471	EGFR-IN-51	Inhibitor	/	否
HY-158178	EGFR T790M/L858R-IN-7	Inhibitor	/	否
HY-144605	PROTAC EGFR degrader 3	Inhibitor	97.39%	否
HY-B0794S	AZ7550-d5	Inhibitor	/	否
HY-144760	EGFR-IN-3	Inducer	/	否
HY-143733	HER2-IN-5	Inhibitor	/	否
HY-157324	EGFR-IN-94	Inhibitor	/	否
HY-131710	PDE5-IN-3	Inhibitor	/	否
HY-142681	EGFR-IN-28	Inhibitor	/	否
HY-161923	EGFR-IN-120	Inhibitor	/	否
HY-P10659	Self-assembling peptide pY1		/	否
HY-156114	EGFR/CDK2-IN-2	Inhibitor	/	否
HY-168151	EGFR-IN-128	Inhibitor	/	否
HY-161136	EGFR/STAT3-IN-1	Inhibitor	/	否
HY-153744	JGK-068S	Inhibitor	/	否
HY-P5258	Oligopeptide-41	Inducer	/	否
HY-142283BS	N-Desmethyl dosimertinib-d5		/	否
HY-139884	EGFR-IN-18	Inhibitor	/	否
HY-158016	Antiproliferative agent-49	Inhibitor	/	否
HY-162300	EGFR kinase inhibitor 4	Inhibitor	/	否
HY-147967	EGFR-IN-63	Inhibitor	/	否
HY-168112	EGFR-IN-127	Inhibitor	/	否
HY-163663	AZ14133346	Inhibitor	/	否
HY-147826	EGFR-IN-60	Inhibitor	/	否
HY-50898S3	Lapatinib-d4-1	Inhibitor	/	否
HY-W174279	Tyrphostin 8	Inhibitor	≥98.0%	否
HY-114535	Jaceidin	Inhibitor	/	否
HY-149518	EGFR/BRAFV600E-IN-3	Inhibitor	/	否
HY-144676	pan-HER-IN-1	Inhibitor	/	否
HY-142680	EGFR-IN-23	Inhibitor	/	否
HY-164392	TAS-121	Inhibitor	/	否
HY-163860	EGFR-TK-IN-3	Inhibitor	/	否
HY-108931	AG 1406	Inhibitor	99.03%	否
HY-147996	EGFR-IN-67	Inhibitor	/	否
HY-164056	EGFR T790M/L858R-IN-8	Inhibitor	99.20%	否
HY-149695	EGFR-IN-91	Inhibitor	/	否
HY-163880	EGFR-IN-119	Inhibitor	/	否
HY-162881	DS06652923	Inhibitor	/	否
HY-144054	EGFR-IN-37	Inhibitor	/	否
HY-144052	EGFR-IN-35	Inhibitor	/	否
HY-157526	EGFR-TK-IN-1	Inhibitor	/	否
HY-RS04210	Egfr Mouse Pre-designed siRNA Set A	Inhibitor	/	否
HY-142678	EGFR-IN-21	Inhibitor	/	否
HY-B0793S1	AZ-5104-d2	Inhibitor	/	否
HY-147994	EGFR/HER2-IN-5	Inhibitor	/	否
HY-101959	Tyrphostin AG213	Inhibitor	/	否
HY-162623	EGFR/HER2-IN-15	Inhibitor	/	否
HY-110039	BIBX 1382 dihydrochloride	Inhibitor	/	否
HY-100064S	O-Desmethyl gefitinib-d8	Inhibitor	99.84%	否
HY-161030	EGFR-IN-92	Inhibitor	/	否
HY-156991	NODAGA-NHS		/	否
HY-160564	ZNL-0056	Inhibitor	/	否
HY-156457	EGFR-IN-90	Inhibitor	/	否
HY-151161	EGFR/HER2-IN-8	Inhibitor	/	否
HY-161031	EGFR-IN-93	Inhibitor	/	否
HY-15772S3	Asandeutertinib	Inhibitor	/	否
HY-101522	CHMFL-EGFR-202	Inhibitor	99.75%	否
HY-100064	O-Desmethyl gefitinib	Inhibitor	99.40%	否
HY-158177	EGFR T790M/L858R-IN-6	Inhibitor	/	否
HY-151156	EGFR/HER2-IN-6	Inhibitor	/	否
HY-146782	EGFR-IN-49	Inhibitor	/	否
HY-164490	LS-106	Inhibitor	/	否
HY-146423	PROTAC EGFR degrader 6	Inhibitor	/	否
HY-101960	(Z)-Tyrphostin A51	Inhibitor	/	否
HY-161269	EGFR-IN-101	Inhibitor	/	否
HY-151981	EGFR-IN-74	Inhibitor	/	否
HY-162062	EGFR WT/T790M/L858R-IN-1	Inhibitor	/	否
HY-163371	EGFR WT/T790M-IN-1	Inhibitor	/	否
HY-163417	HER2-IN-15	Inhibitor	/	否
HY-13595R	Chrysophanol (Standard)	Inhibitor	/	否
HY-161618	MJ04	Inhibitor	/	否
HY-147992	EGFR/HER2-IN-4	Inhibitor	/	否
HY-155969	EGFR-IN-83	Inhibitor	/	否
HY-168559	EGFR-IN-131	Inhibitor	/	否
HY-155200	EGFR-IN-84	Inhibitor	/	否
HY-142283CS	N-Methyl-dosimertinib-d5		/	否
HY-157398	EGFR T790M/L858R-IN-3	Inhibitor	/	否
HY-168064	EGFR-IN-124	Inhibitor	/	否
HY-137786	EGFR-IN-16	Inhibitor	/	否
HY-161319	EGFR-IN-104	Inhibitor	/	否
HY-144055	EGFR-IN-38	Inhibitor	/	否
HY-144056	EGFR-IN-39	Inhibitor	/	否
HY-13524A	AG-1478 hydrochloride	Inhibitor	/	否
HY-W423595	BEBT-109	Inhibitor	/	否
HY-10261E	(R)-Afatinib	Inhibitor	/	否
HY-123035	Gamendazole	Inhibitor	/	否
HY-N3634	Corylifol C		/	否
HY-147798	EGFR/HER2/CDK9-IN-3	Inhibitor	/	否
HY-156116	EGFR/CDK2-IN-4	Inhibitor	/	否
HY-159519	EGFR/HER2-IN-16	Inhibitor	/	否
HY-158176	EGFR T790M/L858R-IN-5	Inhibitor	/	否
HY-149846	SIQ17	Inhibitor	/	否
HY-156741	EGFR-IN-87	Inhibitor	/	否
HY-143901	EGFR-IN-40	Inhibitor	/	否
HY-146210	EGFR-IN-50	Inhibitor	/	否
HY-150782	UNC-CA359	Inhibitor	/	否
HY-159512	EGFR kinase inhibitor 7	Inhibitor	/	否
HY-147802	EGFR-IN-59	Inhibitor	/	否
HY-161320	EGFR-IN-105	Inhibitor	/	否
HY-146136	EGFR-IN-56	Inhibitor	/	否
HY-144097	HER2-IN-8	Inhibitor	/	否
HY-162148	HNPMI	Inhibitor	99.57%	否
HY-144444	NSC381467	Inhibitor	/	否
HY-151159	DHFR-IN-4	Inhibitor	99.19%	否
HY-164399	SST0116CL1	Degrader	/	否
HY-169308	EGFR-IN-132	Inhibitor	/	否
HY-19985A	(3S,4S)-PF-06459988		99.85%	否
HY-163418	HER2-IN-17	Inhibitor	/	否
HY-146422	PROTAC EGFR degrader 5	Inhibitor	/	否
HY-149407	Multi-kinase-IN-4	Inhibitor	/	否
HY-161146	EGFR-IN-100	Inhibitor	/	否
HY-153557	HER2-IN-13	Inhibitor	/	否
HY-127067	Yuanhuadin	Inhibitor	/	否
HY-162099	VEGFR-IN-4	Inhibitor	/	否
HY-144049	EGFR-IN-32	Inhibitor	/	否
HY-147997	EGFR-IN-68	Inhibitor	/	否
HY-142519	EGFR-IN-27	Inhibitor	/	否
HY-162332	EGFR-PK/JNK-2-IN-1	Inhibitor	/	否
HY-100636	Gefitinib N-oxide	Inhibitor	/	否
HY-147995	EGFR-IN-64	Inhibitor	/	否
HY-164387A	Sutetinib maleate	Inhibitor	/	否
HY-145867	EGFR-IN-45	Inhibitor	/	否
HY-145824	EGFR-IN-43	Inhibitor	/	否
HY-163453	HER2-IN-19	Inhibitor	/	否
HY-162964	EGFR-IN-126	Inhibitor	/	否
HY-P10569	Biotin HER-2 substrate peptide		/	否
HY-151158	EGFR/HER2-IN-7	Inhibitor	/	否
HY-142517	EGFR-IN-25	Inhibitor	/	否
HY-402309	IGF-1R modulator 1	Modulator	/	否
HY-160613	EGFR/HER2-IN-11	Inhibitor	/	否
HY-164413	CLM3	Inhibitor	/	否
HY-146228	HSP90-IN-13	Inhibitor	/	否
HY-144445	NSC114126	Inhibitor	/	否
HY-162323	EGFR-IN-106	Inhibitor	/	否
HY-162891	EGFR-IN-123	Inhibitor	/	否
HY-153856A	TAS2940 fumarate	Inhibitor	/	否
HY-161785	EGFR-IN-117	Inhibitor	/	否
HY-161891	EGFR/Akt-IN-1	Inhibitor	/	否
HY-151377	RET-IN-19	Inhibitor	/	否
HY-159101	EP26	Inhibitor	/	否
HY-143874	HER2-IN-7	Inhibitor	/	否
HY-162360	EGFR-IN-109	Inhibitor	/	否
HY-163419	HER2-IN-18	Inhibitor	/	否
HY-100663	Gefitinib impurity 2		99.56%	否
HY-161968	EGFR/PI3Kα-IN-1	Inhibitor	/	否
HY-18213	EGFR-IN-9	Inhibitor	98.84%	否
HY-146238	EGFR/HER2/TS-IN-1	Inhibitor	/	否
HY-115933	EGFR/BRAF-IN-1	Inhibitor	/	否
HY-144044	EGFR-IN-30	Inhibitor	/	否
HY-156470	Multi-kinase-IN-6	Inhibitor	/	否
HY-169309	EGFR-IN-133	Inhibitor	/	否
HY-160068	2-2(t) aptamer sodium	Chemical	/	否
HY-147825	EGFR/BRAFV600E-IN-1	Inhibitor	/	否
HY-164718	Sevabertinib	Inhibitor	/	否
HY-168627	EGFR-IN-135	Inhibitor	/	否
HY-157166	EGFR kinase inhibitor 2	Inhibitor	/	否
HY-144441	NSC81111	Inhibitor	/	否
HY-169346	Pred17	Inhibitor	/	否
HY-145844	EGFR-IN-44	Inhibitor	/	否
HY-158175	EGFR T790M/L858R-IN-4	Inhibitor	/	否
HY-144794	EGFR-IN-46	Inhibitor	/	否
HY-101958	Tyrphostin 25	Inhibitor	99.00%	否
HY-P2548	pp60 (v-SRC) Autophosphorylation Site, Phosphorylated		/	否
HY-161602	EGFR/HER2-IN-13	Inhibitor	/	否
HY-147860	EGFR-IN-61	Inhibitor	/	否
HY-146170	Anticancer agent 69	Inhibitor	/	否
HY-146473	EGFR-IN-53	Inhibitor	/	否
HY-155074	EGFR-IN-79	Inhibitor	/	否
HY-168623	EGFR-IN-134	Inhibitor	/	否
HY-163000	EGFR-IN-129	Inhibitor	/	否
HY-146472	EGFR-IN-52	Inhibitor	/	否
HY-149632	EGFR/HER2/DHFR-IN-2	Inhibitor	/	否
HY-149275	PKM2/PDK1-IN-1	Inhibitor	/	否
HY-12008S1	Erlotinib-13C6 hydrochloride		/	否
HY-160682	EGFR/HER2-IN-12	Inhibitor	/	否
HY-155118	EGFR-IN-81	Inhibitor	/	否
HY-P1085	Epidermal Growth Factor Receptor Peptide (985-996)	Chemical	/	否
HY-143445	EGFR-IN-48	Inhibitor	/	否
HY-110328	PKI-166 hydrochloride	Inhibitor	/	否
HY-161632	PROTAC EGFR degrader 10	Degrader	/	否
HY-161145	EGFR/microtubule-IN-1	Inhibitor	/	否
HY-112474	Tyrphostin AG 112	Inhibitor	98.55%	否
HY-129510	4-Methyl erlotinib	Inhibitor	/	否
HY-164387	Sutetinib	Inhibitor	/	否
HY-163420	HER2-IN-16	Inhibitor	/	否
HY-P4082	ErbB-2-binding peptide		99.83%	否
HY-121828	TX-1123	Inhibitor	/	否
HY-151154	EGFR/HER2/DHFR-IN-1	Inhibitor	/	否
HY-50896S1	Erlotinib-13C6	Inhibitor	/	否
HY-162788	EGFR-IN-121	Inhibitor	/	否
HY-161603	EGFR/HER2-IN-14	Inhibitor	/	否
HY-146132	EGFR-IN-55	Inhibitor	/	否
HY-149401	EGFR-IN-82	Inhibitor	/	否
HY-162602	EGFR-IN-115	Inhibitor	/	否
HY-50898S2	Lapatinib-d5	Inhibitor	/	否
HY-155178	Antiproliferative agent-34	Inhibitor	/	否
HY-152019	EGFR/C797S-IN-1	Inhibitor	/	否
HY-161045	T-1-DOCA	Inhibitor	/	否
HY-150905	EGFR ligand-2	Inhibitor	/	否
HY-149633	EGFR/HER2/DHFR-IN-3	Inhibitor	/	否
HY-10261S1	Afatinib-d4	Inhibitor	/	否
HY-163377	AZ5385	Inhibitor	/	否
HY-18298	PD 173955 analog 1	Inhibitor	/	否
HY-151162	HER2-IN-12	Inhibitor	/	否
HY-156115	EGFR/CDK2-IN-3	Inhibitor	/	否
HY-161866	EGFR-IN-118	Inhibitor	/	否
HY-156639	EGFR/ErbB-2 inhibitor-1	Inhibitor	/	否
HY-13050A	Sapitinib fumarate	Inhibitor	/	否
HY-146138	EGFR-IN-57	Inhibitor	/	否
HY-135216	Antiproliferative agent-54	Inhibitor	/	否
HY-115952	EGFR/HER2-IN-3	Inhibitor	/	否
HY-15268	PP487	Inhibitor	/	否
HY-146154	EGFR-IN-58	Inhibitor	/	否
HY-161067	EGFR-IN-96	Inhibitor	/	否
HY-163006	EGFR/c-Met-IN-1	Inhibitor	/	否
HY-149344	Anticancer agent 133	Inhibitor	/	否
HY-19730A	Olmutinib hydrochloride	Inhibitor	/	否
HY-W008914	(E/Z)-CP-724714	Inhibitor	/	否
HY-50898S1	Lapatinib-d7 dihydrochloride	Inhibitor	/	否
HY-168173	EGFR-IN-130	Inhibitor	/	否
HY-147862	EGFR-IN-62	Inhibitor	/	否
HY-144053	EGFR-IN-36	Inhibitor	/	否
HY-156033	EGFR-IN-88	Inhibitor	/	否
HY-163722	EGFR/DHFR-IN-1	Inhibitor	/	否
HY-157912	EGFR-IN-102	Inhibitor	/	否
HY-162890	EGFR-IN-122	Inhibitor	/	否
HY-144051	EGFR-IN-34	Inhibitor	/	否
HY-142679	EGFR-IN-22	Inhibitor	/	否
HY-151573	EGFR/CDK2-IN-1	Inhibitor	/	否
HY-147797	EGFR/HER2/CDK9-IN-2	Inhibitor	/	否
HY-135725	D-69491 hydrochloride	Inhibitor	/	否
HY-15769A	WHI-P180 hydrochloride	Inhibitor	/	否
HY-50895S2	Gefitinib-d3	Inhibitor	/	否
HY-157582	MS39N	Inhibitor	/	否
HY-163396	EGFR-IN-107	Inhibitor	/	否
HY-164464	BPI-15086	Inhibitor	/	否
HY-164763	SHR-A1201	Inhibitor	/	否
HY-21291	SU-4313	Modulator	/	否
HY-123766	EGFR-IN-99	Inhibitor	/	否
HY-114667	Lavendustin C6	Inhibitor	/	否
HY-164503	Neptinib	Inhibitor	/	否
HY-13314A	Tesevatinib tosylate	Inhibitor	/	否
HY-19909A	NRC-2694-A	Inhibitor	/	否
HY-103443A	HKI-357 dimaleate	Inhibitor	/	否
HY-P10648	Herceptide		/	否
HY-137433A	Befotertinib mesylate	Inhibitor	/	否
HY-50898CS	Lapatinib-d4 tosylate	Inhibitor	/	否
HY-117523	(Z)-RG-13022	Inhibitor	/	否
HY-164527	Si306	Inhibitor	/	否
HY-164762	Trastuzumab rezetecan	Inhibitor	/	否
HY-110045	ZM-306416 hydrochloride	Inhibitor	/	否
HY-129288	GW837016X	Inhibitor	/	否
HY-164919	Calotatug ginistinag	Inhibitor	/	否
HY-164476	ES-072	Inhibitor	/	否
HY-135727	PF-6422899	Inhibitor	/	否
HY-168305	EGFR ligand-11		/	否
HY-32721S	Neratinib-d6	Inhibitor	/	否
HY-146262	LDC0496	Inhibitor	/	否
HY-100520	EGFR-IN-2	Inhibitor	/	否
HY-110406	13(S)-HPODE	Activator	/	否

抗体抑制剂 (20)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-P9912A	Pertuzumab (anti-HER2)	Inhibitor	99.10%	否
HY-P99684	Laprituximab	Inhibitor	≥95.0%	否
HY-P99892	Serclutamab		99.97%	否
HY-P99888	Pimurutamab		/	否
HY-P99324	Tomuzotuximab	Inhibitor	/	否
HY-P99948	Etevritamab		/	否
HY-P990698	Umizortamig		/	否
HY-P990055	Nezutatug	Inhibitor	/	否
HY-P990695	Lunaxafusp	Inhibitor	/	否
HY-P99558	Timigutuzumab	Inhibitor	/	否
HY-P990755	Pamvatamig		/	否
HY-P990697	Anvatabart	Inhibitor	/	否
HY-P990972	Azerutamig		/	否
HY-P990957	Ficerafusp alfa		/	否
HY-P990913	Dalmitamig		/	否
HY-P990947	Tilatamig		/	否
HY-P990962	Vislarafusp alfa		/	否
HY-P9977A	Amivantamab (FUT8-KO)	Inhibitor	/	否
HY-P990909	Calotatug		/	否
HY-P990978	Caxmotabart		/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Egfr	NCBI	NCBI:1956
Canis familiaris	Egfr	NCBI	NCBI:404306
Macaca fascicularis	Egfr	NCBI	NCBI:102138724
Mus musculus	Egfr	NCBI	NCBI:13649
Macaca mulatta	Egfr	NCBI	NCBI:613027

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.